Geodis, a global leader in transport and logistics, has announced that it has achieved the IATA Center of Excellence for Independent Validators (CEIV) Pharma certification for its site in the south Indian city of Hyderabad, thus reinforcing its commitment to delivering world-class healthcare and life sciences logistics solutions.    

The certification validates that Geodis’ Hyderabad operations, processes, infrastructure, and personnel meet rigorous international standards for handling pharmaceutical and healthcare shipments, said the company in a statement. 

The certification process includes comprehensive assessments of quality management systems, operational procedures, risk management practices, staff training, temperature-control capabilities, and regulatory compliance.

Hyderabad, widely recognised as one of India's leading pharmaceutical and life sciences hubs, plays a critical role in supporting global healthcare supply chains. 

With this achievement, Geodis further strengthens its ability to serve pharmaceutical manufacturers, biotechnology companies, and healthcare customers requiring specialized logistics solutions, it stated.

“Hyderabad is one of the world's most important pharmaceutical manufacturing and export hubs, making it a strategic location for our healthcare logistics network,” remarked Chris Cahill, Managing Director, Middle East and India Sub-continent, Geodis. 

“This certification enhances our ability to support customers moving increasingly complex and temperature-sensitive healthcare products across global markets. It also reflects our continued investment in specialist infrastructure and expertise in India, where we now have more than 1,000 employees across 15 locations serving over 7,000 customers,” he stated. 

The achievement complements Geodis’ broader healthcare logistics strategy, which combines specialised infrastructure, trained healthcare logistics professionals, advanced shipment visibility and stringent quality controls to support the safe movement of critical healthcare products worldwide.

“As part of our wider network of 29 CEIV Pharma-certified sites globally - including nine in the Asia Pacific and Middle East Region - Hyderabad further strengthens the resilience and consistency of our healthcare offering for customers across Asia Pacific and beyond,” he added.